ArticleJournal of neurology2025
Retinal nerve fiber layer thinning in multiple sclerosis: clinical implications, cognitive associations, and effects of disease-modifying therapies.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPeripapillary retinal nerve fiber layer (pRNFL) thinning, detected by optical coherence tomography (OCT), is an early marker of neuroaxonal injury in multiple sclerosis (MS). Its prognostic value for long-term outcomes and responsiveness to disease-modifying therapies (DMTs) remains insufficiently explored, particularly in Asian populations. This study aimed to identify clinical and radiological correlates of pRNFL thickness, evaluate whether pRNFL thinning predicts disability and cognitive decline, and examine the effects of DMTs on retinal neurodegeneration in Chinese MS patients.
methodsWe analyzed 354 Chinese MS patients who underwent OCT, neurological assessments, and brain MRI. Multivariate regression identified determinants of baseline pRNFL thickness. Among 159 patients with follow-up longer than 12 months, logistic regression was used to assess whether baseline pRNFL thickness and annualized pRNFL thinning predicted disability or cognitive decline. Linear mixed-effects models were applied to evaluate longitudinal effects of DMT classes on pRNFL thinning.
resultsMedian pRNFL thickness was 105.0 μm (range: 65.0-136.5). Thinner pRNFL was associated with longer disease duration (p < 0.001), optic neuritis (p = 0.019), longer 9-Hole Peg Test completion time (p = 0.025), and increased paramagnetic rim lesions (p = 0.002). Baseline pRNFL thickness did not predict EDSS progression or Symbol Digit Modalities Test (SDMT) decline. In contrast, faster annualized pRNFL thinning predicted SDMT worsening (OR = 1.29, p = 0.018), alongside fewer years of education (OR = 0.84, p = 0.033) and a secondary progressive MS phenotype (OR = 7.67, p = 0.006). No significant differences in pRNFL preservation were observed among DMT classes.
conclusionpRNFL thinning reflects disease severity and predicts cognitive decline in MS. Current DMTs provide limited retinal neuroprotection. These findings support the routine OCT-derived pRNFL monitoring and highlight the need for neuroprotective strategies in MS.
Indexed as
Identifiers
41391056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.